<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02448199</url>
  </required_header>
  <id_info>
    <org_study_id>Zodiac Produtos Farmacêuticos</org_study_id>
    <nct_id>NCT02448199</nct_id>
  </id_info>
  <brief_title>Study of Association of Anti-inflammatory and Anti-rheumatic</brief_title>
  <acronym>ZDPC00213</acronym>
  <official_title>Phase III Study Comparing Association of Anti-inflammatory and Anti-rheumatic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zodiac Produtos Farmaceuticos S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eurotrials Brasil Consultores Cientificos Ltda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zodiac Produtos Farmaceuticos S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III Study, double-blind, comparing association of anti-inflammatory and anti-rheumatic
      in 375 subjects with knee osteoarthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation after 12 weeks of treatment, in 3 arms, the efficacy and safety of the
      association.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy measured by decrease in score algofunctional Lequesne index after 12 weeks from the start of treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Decrease in score of algofunctional Lequesne index after 12 weeks from the start of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety measured by frequency of adverse event</measure>
    <time_frame>12 weeks</time_frame>
    <description>Safety as measured by total frequency of adverse event during the 12 weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">375</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Kit 1 ( ML + CG ) + P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One sachet meloxicam and glucosamine and 1 placebo tablet once a day for 12 weeks One sachet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kit 2 ( ML + P)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One tablet of meloxicam and one sachet of placebo once per day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kit 3 ( P+ GC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One sachet of glucosamine and one tablet placebo once a day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam and Glucosamine</intervention_name>
    <description>Experimental</description>
    <arm_group_label>Kit 1 ( ML + CG ) + P</arm_group_label>
    <other_name>Association Anti-inflamatory/Anti-rheumatic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>Kit 2 ( ML + P)</arm_group_label>
    <other_name>Anti-inflamatory/Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucosamine</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>Kit 3 ( P+ GC)</arm_group_label>
    <other_name>Anti-rheumatic/Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signs the Informed Consent Form

          -  Age between 40 and 85 years

          -  osteoarthritis of the knee according to clinical and radiological criteria of the
             American College of Rheumatology

        Exclusion Criteria:

          -  Cardiovascular disease

          -  Serious chronic comorbidity

          -  Hypersensitivity to any component of the study drugs

          -  body mass index&gt; 30 kg / m²
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edio Costa, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>CRM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carine F Sanches, Pharmacist</last_name>
    <phone>55 11 55015332</phone>
    <email>carine.sanches@zodiac.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valery F Carvalho, Biologist</last_name>
  </overall_contact_backup>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <last_update_submitted>May 18, 2015</last_update_submitted>
  <last_update_submitted_qc>May 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>Knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meloxicam</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

